Clearpoint Neuro Inc

NASDAQ CLPT

Data sourced from

and

Download Data

Clearpoint Neuro Inc Selling, General, and Administrative Expenses (SG&A) 5 year CAGR for the year ending December 31, 2023: 22.13%

Clearpoint Neuro Inc Selling, General, and Administrative Expenses (SG&A) 5 year CAGR is 22.13% for the year ending December 31, 2023, a 17.18% change year over year. Selling, General, and Administrative Expenses (SG&A) consit of the expenses related to the sales and marketing efforts, as well as general and administrative functions of a company. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Clearpoint Neuro Inc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2022 was USD 9.61 M, a 9.70% change year over year.
Clearpoint Neuro Inc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2021 was USD 8.76 M, a 66.24% change year over year.
Clearpoint Neuro Inc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2020 was USD 5.27 M, a 22.56% change year over year.
Clearpoint Neuro Inc Selling, General, and Administrative Expenses (SG&A) for the year ending December 31, 2019 was USD 4.30 M, a -0.60% change year over year.

NASDAQ: CLPT

Clearpoint Neuro Inc

CEO	Mr. Joseph Michael Burnett
IPO Date	Feb. 12, 2020
Location	United States
Headquarters	120 S. Sierra Avenue, Solana Beach, CA, United States, 92075
Employees	107
Sector	Healthcare
Industry	Medical devices

Description

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Key trends